预约演示

A drop under the tongue and you're done: Researchers test sublingual COVID vaccine in primates

2023-09-13

疫苗临床结果临床2期临床1期免疫疗法

The researchers’ vaccine is a combination of an antibody against the receptor-binding domain of the spike protein on the SARS-CoV-2 virus and an adjuvant called poly(I:C).

What if the COVID-19 vaccine could be a simple drop under the tongue instead of a shot in the arm?

That's the rCOVID-19 vaccine COVID-19searchers from Japan’s Intelligence & Technology Lab Inc. and the Biomedical Institute of NPO Primate Agora are hoping for. Results of a study published Sept. 13 in Biology Methods and Protocols described how they developed a protein-based COVID vaccine for delivery under the tongue, or sublingually. When they tested it in primates, the animals produced antibodies against COVID without side effects.

The researchers’ vaccine is a combination of an antibody against the receptor-binding domain of the spike protein on the SARS-CoV-2 virus and an adjuvant called poly(I:C), a synthetic double-stranded RNA that binds to genes associated with viral infection. It activates a subset of immune cells called antigen-presenting cells that initiate the adaptive immune response by displaying captured anCOVIDs to B and T cells, which then target the invader.

Despite being a “potent” adjuvant, the researchers wrote, poly(I:C) hasn’t been approved yet for use in vaccines but is used in oncology as a complement to immunotherapy. Some studies in mice have shown that the compound increases levels ofviral infectiony cytokines when administered via the nose, which raises the risk of side effects like pain, fever and swelling.

Perhaps a different route of administration would temper tpoly(I:C)ial for adverse effects, the scientists reasoned.pain fever swelling

The primates received three vaccinations to start, administered four weeks apart. A booster dose was given 15 weeks after the final round in the primary series. The scientists also included a control group of three primates.

After the booster dose, the team analyzed the amount and type of antibodies found in fluids from the monkeys’ mouths. They observed a desirable dose-dependent increase in IgA antibodies, “guardians of the oral and nasopharyngeal galaxy” that prevent the virus from attaching to cells in the mucosa. What’s more, they didn’t detect any obvious side effects nor did they see an increase in IgE antibodies, which are associated with an allergic response.

It’s not yet clear how efficacious the vaccine is against COVID-19 nor how long protection might endure. The researchers are currently conducting additional studies to address these questions, looking at changes in markers of gene expression to better quantify how well it works.

Results from other research groups might offer a preview. COVID-19Bio and NantKwest launched a phase 1b trial of sublingual, subcutaneous and oral versions of their COVID-19 vaccine in March 2021. The primary completion date was set for January 2023, though there haven’t been any updates since. Meanwhile, in March, researchers at the University of California, Los Angeles reported that their universal oral COVID-19 vaccine prevented severe illness in hamsters, one of the most vulnerable models to the disease.

More progress is being made on intranasal vaccines. The fuImmunityBiog is NantKwesttenuated vaccine from Codagenix, which is currently being tested in Africa in a phCOVID-19ial backed by the World Health Organization. Startup Blue Lake Biotechnology reported phase 1 results in February showing that its intranasal vaccine reduced the rUniversity of California, Los Angelesople who received it as a booster doCOVID-19 now undergoing a phase 2 trial.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构